🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,425 results for “Elan” Clear

  1. Alyftrek 125 mg/50 mg/10 mg film-coated tablets, VX-121/VX-661/VX-561 Film-coated tablet

    Vertex Pharmaceuticals (Ireland) Limited

    Cystic Fibrosis

    phase 3 small molecule active

    1 trial

  2. Amchafibrin

    Lxo Ireland Designated Activity Company

    Osteoarthritis, Knee

    phase 3 small molecule completed

    1 trial

  3. Apremilast, Apremilast, Apremilast

    Amgen Technology (Ireland) UC

    Behçet’s disease is a chronic, relapsing, multisystem inflammatory disorder of unknown etiology characterized by 4 major symptoms (oral aphthous ulcers, genital ulcers, skin lesions, and ocular lesions) and occasionally by 5 minor symptoms (arthritis, gastrointestinal ulcers, epididymitis, vascular lesions, and central nervous system [CNS] symptoms) (Cho, 2012). Juvenile idiopathic arthritis is a heterogeneous group of chronic inflammatory disorders that initially presents in children by the age of 16 years. It refers to arthritis of at least 6 weeks duration of unknown etiology that begins in children less than 16 years old. Juvenile idiopathic arthritis has an annual incidence of 2 to 20 cases per 100 000 population and a prevalence of 16 to 150 cases per 100 000 population. It is an autoimmune disorder marked by abnormalities of immune responses (Adelowo, 2010).

    phase 3 small molecule active

    1 trial

  4. Apremilast, Apremilast, Apremilast, Apremilast placebo product is supplied to the clinic as 10, 20 and 30 mg tablets and 5 mg/mL oral solution. The placebo product is the same as the drug product formulation except there is no active apremilast., Apremilast

    Amgen Technology (Ireland) UC

    Juvenile psoriatic arthritis

    phase 3 small molecule active

    1 trial

  5. Atezolizumab

    Jazz Pharmaceuticals Ireland Limited

    Small-Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  6. Atropine Eye Drops, Solution (0.05% w/v), Atropine Eye Drops, Solution (0.025% w/v), The placebo consists of the same composition as the atropine eye drops except for the active substance.

    Elan Pharma International

    Myopia

    phase 3 small molecule active

    1 trial

  7. Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC)

    LISATA THERAPEUTICS, INC.

    Stage IV Melanoma

    phase 3 mab terminated

    1 trial

  8. BAY 1841788, TRIPTORELIN

    Cancer Prevention Pharma (Ireland) Limited

    Patients with localised prostate cancer and high-risk features of relapse (minimum 2 high-risk criteria from National Comprehensive Cancer Network (NCCN) classification)1 and with no detectable metastasis, including no evidence of pelvic lymph node metastasis on next-generation imaging (PSMA PET/CT).

    phase 3 small molecule active

    1 trial

  9. BELZUPACAP SAROTALOCAN, Placebo (Sham injection) to Belzupacap Sarotalocan solution for sham injection 0.0 mg/mL, BELZUPACAP SAROTALOCAN

    Aura Biosciences

    Primary Indeterminate Lesions or Small Choroidal Melanoma

    phase 3 small molecule active

    1 trial

  10. BEVACIZUMAB, OXALIPLATIN, CALCIUM FOLINATE, FLUOROURACIL, PF-08634404

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Metastatic Colorectal Cancer

    phase 3 small molecule active

    1 trial

  11. BGB-11417, BGB-11417 placebo, BGB-11417, BGB-11417, BGB-11417, Zanubrutinib

    Beone Medicines Ireland Limited

    relapsed or refractory mantle cell lymphoma (R/R MCL)

    phase 3 small molecule active

    1 trial

  12. BGB-11417, Zanubrutinib, BGB-11417, Venclyxto 100 mg film-coated tablets, Gazyvaro 1,000 mg concentrate for solution for infusion., BGB-11417, BGB-11417

    Beone Medicines Ireland Limited

    Previously Untreated Chronic Lymphocytic Leukemia

    phase 3 small molecule active

    1 trial

  13. BGB-16673

    Beone Medicines Ireland Limited

    CLL

    phase 3 small molecule active

    1 trial

  14. BGB-16673

    Beone Medicines Ireland Limited

    Chronic Lymphocytic Leukemia

    phase 3 small molecule active

    2 trials

  15. BGB-43395

    Beone Medicines Ireland Limited

    HR+/HER2- Breast Cancer

    phase 3 small molecule active

    1 trial

  16. BHV-7000, Placebo for BHV-7000, BHV-7000

    Biohaven Bioscience Ireland Limited

    Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures

    phase 3 small molecule active

    1 trial

  17. BHV-8000, DaTSCAN 74 MBq/ml solution for injection, DaTSCAN 74 MBq/ml solution for injection, BHV-8000, Placebo for BHV-8000

    Biohaven Bioscience Ireland Limited

    Early Parkinson’s Disease

    phase 3 small molecule active

    1 trial

  18. BJT-778

    Blue Earth Diagnostics Ireland Ltd

    Chronic Hepatitis Delta Infection

    phase 3 small molecule active

    1 trial

  19. BJT-778

    Blue Earth Diagnostics Ireland Ltd

    Chronic Hepatitis Delta Infection

    phase 3 small molecule active

    1 trial

  20. BULEVIRTIDE, BJT-778

    Blue Earth Diagnostics Ireland Ltd

    Chronic Hepatitis D Infection

    phase 3 small molecule active

    1 trial

  21. BULEVIRTIDE, BJT-778

    Blue Earth Diagnostics Ireland Ltd

    Chronic Hepatitis D Infection

    phase 3 small molecule active

    1 trial

  22. Bel-sar

    Aura Biosciences

    Choroidal Melanoma

    phase 3 small molecule active

    1 trial

  23. Bempegaldesleukin

    Nektar Therapeutics UK Limited

    Melanoma

    phase 3 mab terminated

    1 trial

  24. Biological/Vaccine

    Vertex Pharmaceuticals (Ireland) Limited

    Type 1 Diabetes

    phase 3 mab active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources